Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,361 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,154 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (646)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05973331 | Prospective Validation of an EHR-based Pancreatic Cancer Risk Model | active not recruiting | — | 6,134,060 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT07543510 |
| Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma |
| not yet recruiting |
| N/A |
| 38 |
| Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER |
| 0 |
| Apr 22, 2026 |
| clinicaltrials |
| NCT07544121 | Effect of Babao Dan Capsule Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis | not yet recruiting | N/A | 1,034 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT06330441 | Pancreatic Cancer Screening in a Population at High Risk(ScrePan) | recruiting | N/A | 700 | Masaryk Memorial Cancer InstituteOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06860490 | HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) | recruiting | Phase 2 | 164 | Fudan UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07147101 | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment(HCC-IM-1) | recruiting | — | 150 | Fudan UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07487402 | Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01899261 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | completed | N/A | 20 | Montefiore Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02174549 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | recruiting | Phase 1 / Phase 2 | 25 | Teclison Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04605731 | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | active not recruiting | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06705335 | Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma(CONVERCAP) | recruiting | — | 50 | Institut BergoniéOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538882 | AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma | recruiting | — | 108 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02954094 | A Longitudinal Observational Study of the Natural History and Management of Patients With HCC | active not recruiting | — | 10,000 | Target PharmaSolutions, Inc.INDUSTRY | 5 | Apr 17, 2026 | clinicaltrials |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma | terminated | Phase 1 / Phase 2 | 2 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05179486 | Molecular Epidemiology of Biliary Tree Cancers | recruiting | — | 1,500 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05332496 | TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC(CHANCE2202) | completed | — | 941 | Zhongda HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05332821 | TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC(CHANCE2201) | completed | — | 1,244 | Zhongda HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06233981 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis | completed | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06655142 | OSCAR II STUDY - The ONCObind CTC Removal Study | not yet recruiting | N/A | 120 | ExThera Medical CorporationINDUSTRY | 0 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT07537777 | Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy | not yet recruiting | Phase 2 | 29 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537946 | Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer | not yet recruiting | Phase 3 | 400 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537959 | Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases | not yet recruiting | N/A | 280 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537972 | Denosumab Strategy for Liver Cancer With Bone Metastases | not yet recruiting | Phase 2 | 50 | Tongji HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03259867 | Combination of TATE and PD-1 Inhibitor in Liver Cancer(TATE-PD1) | recruiting | Phase 2 | 54 | Teclison Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04940286 | Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | active not recruiting | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05623150 | CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome(CHALNA2) | recruiting | — | 710 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05842174 | Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma(TAQE) | recruiting | Phase 1 / Phase 2 | 93 | VA Office of Research and DevelopmentFED | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05967182 | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06453486 | A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment(ABLATE) | recruiting | Phase 2 | 43 | University Health Network, TorontoOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07476651 | Scout Dose of Resin Microspheres(LASER) | recruiting | N/A | 30 | Seoul National University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. | recruiting | Phase 2 / Phase 3 | 680 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04785534 | Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis | active not recruiting | N/A | 1,000 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04837118 | Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study | active not recruiting | N/A | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04924062 | Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study | completed | Phase 3 | 158 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05143619 | Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05247164 | EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients(EUPhORIC) | completed | N/A | 23 | IRCCS San RaffaeleOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05304936 | HCW9218 for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 21 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06659705 | Cutting Edge Imaging With PET-FAPI for Earlier Pancreatic Cancer Diagnosis (INDIGO-FAPI)(INDIGO-FAPI) | recruiting | Phase 2 | 35 | Institut CurieOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07036978 | Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer | not yet recruiting | — | 140 | Chang Gung Memorial HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07126158 | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma | recruiting | Phase 2 | 36 | Washington University School of MedicineOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05821556 | Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients | recruiting | Phase 2 | 240 | National Cancer Institute, NaplesOTHER | 2 | Apr 14, 2026 | clinicaltrials |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 101 | Guohui XuOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02771405 | Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC(FRI-STC) | completed | Phase 3 | 150 | National Hepatology & Tropical Medicine Research InstituteOTHER_GOV | 1 | Apr 13, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 22, 2026source: clinicaltrials